인텔리아 테라퓨틱스 (NTLA) 주가 전망: 목표주가, 배당, 최신 뉴스

Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies. The company offers clustered, regularly interspaced short palindromic repeats (“CRISPR”)/CRISPR associated 9 (“Cas9”) technology for genome editing. The company provides a modular platform, to advance in vivo and ex vivo therapies for diseases.

The company's in vivo product candidates include nexiguran ziclumeran, or NTLA-2001 for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema. Additionally, it offers product candidates for the treatment of immuno-oncology and autoimmune diseases, and multiple in vivo programs to address diseases with significant unmet medical need by delivering gene editing therapeutics to organs outside the liver.

The company has license and collaboration agreement with AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of various of B cell-mediated autoimmune diseases; ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer; and ReCode Therapeutics, Inc. to develop novel genomic medicines for the treatment of cystic fibrosis.

It also has collaboration agreements with Regeneron Pharmaceuticals, Inc. , SparingVision SAS, and Rewrite Therapeutics Inc. The company was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics, Inc. in July 2014. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Intellia Therapeutics, Inc.는 CRISPR/Cas9 기반 기술을 활용해 잠재적 치료제를 개발하는 임상 단계의 유전체 편집 기업입니다. 회사는 CRISPR/Cas9 기술을 바탕으로 한 모듈형 플랫폼을 통해 in vivo 및 ex vivo 치료법을 진전시키고 있습니다.

주요 in vivo 후보로는 transthyretin amyloidosis 치료용 nexiguran ziclumeran(또는 NTLA-2001)과 유전성 혈관부종 치료용 NTLA-2002가 있으며, 면역종양학 및 자가면역질환용 후보와 간 이외 장기로 유전자 편집 치료제를 전달하는 다수의 in vivo 프로그램도 보유하고 있습니다.

AvenCell Therapeutics, Kyverna Therapeutics, ONK Therapeutics, ReCode Therapeutics 등과의 라이선스·협력 관계를 통해 allogeneic universal CAR-T cell therapies, allogeneic CD19 CAR-T 치료제, engineered NK cell therapies 및 낭포성 섬유증용 유전체 의약품 개발을 추진하고 있으며 Regeneron, SparingVision, Rewrite Therapeutics와도 협업하고 있습니다. 회사는 2014년 설립되었고, 2014년 7월 구 AZRN, Inc.에서 Intellia Therapeutics, Inc.로 사명을 변경했으며 본사는 매사추세츠주 케임브리지에 있습니다.

• 주소: 40 Erie Street, Suite 130, Cambridge, MA 02139, United States

• 전화번호: 857 285 6200

• 웹사이트: https://www.intelliatx.com

• 섹터: Healthcare

• 산업: Biotechnology

• 직원 수: 377